Literature DB >> 3036087

The insulin- and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity.

N J Pyne, M E Cooper, M D Houslay.   

Abstract

The hormone-stimulated 'dense-vesicle' cyclic AMP phosphodiesterase was solubilized as a proteolytically 'clipped' species, and purified to apparent homogeneity from rat liver with a 2000-3000-fold purification and a 13-18% yield. It appeared to be a dimer (Mr 112,000), of two Mr-57,000 subunits. Solubilization of either a liver or a hepatocyte membrane fraction, with sodium cholate in the presence of the protein inhibitor benzamidine, identified three protein bands which could be immunoprecipitated by a polyclonal antibody raised against the pure enzyme. The major band at Mr 62,000 is suggested to be the native 'dense-vesicle' enzyme, having a Mr-5000 extension which serves to anchor this enzyme to the membrane and which is cleaved off during proteolytic solubilization; the Mr-200,000 band is an aggregate of the Mr-62,000 species, and the Mr-63,000 species is possibly a precursor. The purified 'clipped' enzyme hydrolysed cyclic AMP with kinetics indicative of apparent negative co-operativity, with a Hill coefficient (h) of 0.43 and limiting kinetic constants of Km1 = 0.3 +/- 0.05 microM, Km2 = 29 +/- 6 microM, Vmax.1 = 0.114 +/- 0.015 unit/mg of protein and Vmax.2 = 0.633 +/- 0.054 unit/mg of protein. It hydrolysed cyclic GMP with Michaelis kinetics, Km = 10 +/- 1 microM and Vmax. = 4.1 +/- 0.2 units/mg of protein. Cyclic GMP was a potent inhibitor of cyclic AMP hydrolysis, with an IC50 (concn. giving 50% inhibition) of 0.20 +/- 0.01 microM-cyclic GMP when assayed at 0.1 microM-cyclic AMP. This enzyme was inhibited potently by several drugs known to exert positive inotropic effects on the heart, was extremely thermolabile, with a half-life of 4.5 +/- 0.5 min at 40 degrees C, and was shown to be distinct from the rat liver insulin-stimulated peripheral-plasma-membrane cyclic AMP phosphodiesterase [Marchmont, Ayad & Houslay (1981) Biochem. J. 195, 645-652].

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3036087      PMCID: PMC1147660          DOI: 10.1042/bj2420033

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  36 in total

Review 1.  Microvilli: their ultrastructure, enzymology and molecular organization.

Authors:  A J Kenny; A G Booth
Journal:  Essays Biochem       Date:  1978       Impact factor: 8.000

Review 2.  Hormone-sensitive cAMP phosphodiesterase in liver and fat cells.

Authors:  S H Francis; T Kono
Journal:  Mol Cell Biochem       Date:  1982-02-05       Impact factor: 3.396

3.  Purification and properties of the insulin-stimulated cyclic AMP phosphodiesterase from rat liver plasma membranes.

Authors:  R J Marchmont; S R Ayad; M D Houslay
Journal:  Biochem J       Date:  1981-06-01       Impact factor: 3.857

4.  Proteolytic solubilization and modification of hormone-sensitive cyclic nucleotide phosphodiesterase.

Authors:  E G Loten; S H Francis; J D Corbin
Journal:  J Biol Chem       Date:  1980-08-25       Impact factor: 5.157

5.  A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes.

Authors:  R J Marchmont; M D Houslay
Journal:  Biochem J       Date:  1980-05-01       Impact factor: 3.857

6.  Insulin trigger, cyclic AMP-dependent activation and phosphorylation of a plasma membrane cyclic AMP phosphodiesterase.

Authors:  R J Marchmont; M D Houslay
Journal:  Nature       Date:  1980-08-28       Impact factor: 49.962

7.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle.

Authors:  M Endoh; S Yamashita; N Taira
Journal:  J Pharmacol Exp Ther       Date:  1982-06       Impact factor: 4.030

8.  Biochemical studies on the mechanism of cardiotonic activity of MDL 17,043.

Authors:  T Kariya; L J Wille; R C Dage
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

9.  Purification, characterization and production of rabbit antibodies to rat liver particulate, high-affinity, cyclic AMP phosphodiesterase.

Authors:  R H Whitson; M M Appleman
Journal:  Biochim Biophys Acta       Date:  1982-02-02

10.  Insulin and glucagon regulate the activation of two distinct membrane-bound cyclic AMP phosphodiesterases in hepatocytes.

Authors:  C M Heyworth; A V Wallace; M D Houslay
Journal:  Biochem J       Date:  1983-07-15       Impact factor: 3.857

View more
  13 in total

1.  Engineered deletion of the unique N-terminal domain of the cyclic AMP-specific phosphodiesterase RD1 prevents plasma membrane association and the attainment of enhanced thermostability without altering its sensitivity to inhibition by rolipram.

Authors:  Y Shakur; J G Pryde; M D Houslay
Journal:  Biochem J       Date:  1993-06-15       Impact factor: 3.857

2.  Activation and phosphorylation of the 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase by cyclic AMP-dependent protein kinase.

Authors:  E Kilgour; N G Anderson; M D Houslay
Journal:  Biochem J       Date:  1989-05-15       Impact factor: 3.857

3.  Specific antibodies and the selective inhibitor ICI 118233 demonstrate that the hormonally stimulated 'dense-vesicle' and peripheral-plasma-membrane cyclic AMP phosphodiesterases display distinct tissue distributions in the rat.

Authors:  N J Pyne; N Anderson; B E Lavan; G Milligan; H G Nimmo; M D Houslay
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

4.  Resensitization of hepatocyte glucagon-stimulated adenylate cyclase can be inhibited when cyclic AMP phosphodiesterase inhibitors are used to elevate intracellular cyclic AMP concentrations to supraphysiological values.

Authors:  G J Murphy; M D Houslay
Journal:  Biochem J       Date:  1988-01-15       Impact factor: 3.857

5.  Chimeric constructs show that the unique N-terminal domain of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1A; rPDE-IVA1) can confer membrane association upon the normally cytosolic protein chloramphenicol acetyltransferase.

Authors:  G Scotland; M D Houslay
Journal:  Biochem J       Date:  1995-06-01       Impact factor: 3.857

6.  Effects of selective phosphodiesterase 3 inhibition in the perfused liver of the rat after endotoxin treatment.

Authors:  H Weidenbach; K Beckh; M Burger; T Schricker; M Georgieff; G Adler
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

7.  Insulin stimulates the tyrosyl phosphorylation and activation of the 52 kDa peripheral plasma-membrane cyclic AMP phosphodiesterase in intact hepatocytes.

Authors:  N J Pyne; W Cushley; H G Nimmo; M D Houslay
Journal:  Biochem J       Date:  1989-08-01       Impact factor: 3.857

8.  Subcellular localization and hormone sensitivity of adipocyte cyclic AMP phosphodiesterase.

Authors:  N G Anderson; E Kilgour; M D Houslay
Journal:  Biochem J       Date:  1989-09-15       Impact factor: 3.857

9.  Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases.

Authors:  R R Reinhardt; E Chin; J Zhou; M Taira; T Murata; V C Manganiello; C A Bondy
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 10.  Cyclic nucleotide phosphodiesterases in the human lung.

Authors:  G Dent; H Magnussen; K F Rabe
Journal:  Lung       Date:  1994       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.